Many rare diseases are deadly and devastating in a way that inspires urgency and a willingness to try experimental interventions, yet treatments are only available for fewer than 5% of them.
New studies demonstrate that treating cancer based on its molecular vulnerabilities, rather than where it originated, could translate to better outcomes for patients
Americans are surprisingly optimistic about their health as we collectively emerge from the devastating COVID-19 pandemic, reported John Gerzema, CEO of The Harris Poll, at the outset of the three-day Health+Wealth of America conference Tuesday.
COVID-19 is a wake-up call for institutional renewal and reform. The only way to face the uncertainties of the future is to build more, stronger public-private partnerships, and on a global basis.
The design and execution of clinical trials represents an ideal opportunity to engage the consumer and begin building a relationship that can last a lifetime.
Genetic testing has become more mainstream and greater numbers of consumers are receiving their results — and left wondering what they mean and what to do with them. For those who need help navigating and...
Genetic testing is going mainstream, but is the science ready for prime time? The marketing of genetic tests to consumers raises short-term risks and may even threaten the longer-term promise of the technology.
A new FDA-approved cancer gene therapy called CAR T recently showed astonishing effectiveness against leukemia in seriously ill patients. Despite their poor prognosis, 83 percent responded to the treatment, and the cancer medical establishment was...